A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/714 (2006.01) A61K 31/198 (2006.01) A61K 31/55 (2006.01) A61K 45/06 (2006.01) A61P 25/28 (2006.01)
Patent
CA 2200761
The use of a combination of a tricyclic or tetracyclic antidepressant, a serotonin reuptake inhibitor, or a monoamine oxidase inhibitor with a neurotransmitter-inducing or precursor compound is proposed in the preparation of medication for the treatment or prevention of multiple sclerosis or other demyelinating conditions. For use in treatment to ameliorate the effects of a demyelinating condition, a daily regime is proposed of from 10 to 220 mg lofepramine and from 100 mg to 5 g of L-phenylalanine, optionally supplemented with injections of vitamin B12.
Préparation médicamenteuse destinée au traitement ou à la prévention de la sclérose en plaques et d'autres maladies démyélinisantes, qui associe un antidépresseur tricyclique ou tétracyclique, tel qu'un inhibiteur de la réabsorption de la sérotonine ou un inhibiteur de la monoamine-oxydase, à un inducteur ou précurseur de neurotransmetteur. Pour traiter les effets d'une maladie démyélinisante, il convient d'utiliser une posologie journalière de 10 à 220 mg de lofépramine et de 100 mg à 5 g de L-phénylalanine, complétée par des injections de vitamine B12 en option.
Amarin Neuroscience Limited
Loder Cari
Macrae & Co.
LandOfFree
Treatment of multiple sclerosis (ms) and other demyelinating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of multiple sclerosis (ms) and other demyelinating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of multiple sclerosis (ms) and other demyelinating... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1985029